have the highest affinity for binding to major histocompatibility complex molecules.
In contrast, the predominant B-cell epitopes of OMP26 were located more centrally within the molecule between amino acid residues 45 and 145 (T2+T3 region) as determined using enzyme linked immunosorbent assay and surface plasmon resonance assays. The T2+T3 region was immunodominant in several species including chinchilla, mice, and rats when assessed using both mucosal and parenteral immunization regimes. In addition, the antibodies directed against the T2+T3 region bound to intact NTHi cell surface, according to flow cytometry. Collectively, these results specifically locate the amino acid sequences containing the OMP26 T-and Bcell epitopes, which, as newly mapped antigenic epitopes for lymphocyte recognition, will be useful to improve existing NTHi vaccine strategies. Comprehensive definition of the minimum epitope length required for optimal B-and T-cell responses requires further study.
INTRODUCTION
Nontypeable Haemophilus influenzae (NTHi) is a significant human pathogen causing a wide range of respiratory infections. Several outer membrane proteins (OMPs) of NTHi and its oligosaccharide have been investigated as possible vaccine antigens against NTHi [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . One OMP that has shown promise as a potential vaccine candidate is OMP26. The amino acid sequence of this 26kDa OMP 16 is conserved among NTHi isolates from various disease states 17 .
Our laboratory has previously shown that immunization with OMP26 can stimulate enhanced pulmonary clearance of NTHi in a rat model in which animals were initially immunized via intra-Peyer's patches followed by intra-tracheal boost (IPP/IT) 16, 17 . Mucosal immunization with OMP26 protected animals against subsequent pulmonary challenge with both homologous and heterologous strains of NTHi and induced high levels of OMP26-specific IgA and IgG antibodies 16 .
Furthermore, parenteral immunization of chinchillas with OMP26 demonstrated good immunogenicity and enhanced the clearance of NTHi from the nasopharynx 18 . Thus, OMP26 is appealing as an immunogen against NTHi and has demonstrated potential as a candidate vaccine antigen for this pathogen.
A high degree of antigenic heterogenicity between NTHi strains [19] [20] [21] [22] has led to vaccine approaches based on peptide formulations of immunodominant epitopes of the native protein 7 . In one study, T-cell epitopes were included in a peptide-based approach to maximize induction of antibodies with higher affinity for the incorporated B-cell epitopes 23 . This approach offers an additional advantage of accommodating multiple epitopes to cover a broader range of antigenically-distinct NTHi strains.
OMP26 is highly conserved among a large number of clinical NTHi isolates
collected from a range of anatomical sites 17 . Typically, vaccine formulations do not 6 favour the use of a single protein, however, a highly conserved protein such as OMP26 may provide the necessary broad-based protection against geographicallydiverse and antigenically-distinct isolates of NTHi.
This study assessed epitope specificity of the immune responses to OMP26 by mapping the location of T-and B-cell epitopes within the protein to further characterize the immune response to OMP26. These results reveal unique T-and Bcell-targeting regions within OMP26 that will aid in the development of improved peptide-based vaccine strategies for NTHi.
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RESULTS
Lymphoproliferative responses to OMP26 peptides
Lymphoproliferative response studies were conducted using splenocytes derived from rats and mice. Unfortunately, background cross reactivity against E. coli proteins within the mouse samples masked any specific responses and thus only rat data are presented. To localize the immunologically important regions within OMP26
in this response, a series of overlapping OMP26 peptides spanning the entire sequence of full-length OMP26 was used as the in vitro proliferation stimulus. Proliferation in response to Concanavalin A ranged from 85,000 to 110,000 counts per minute
At a concentration of 1 µg/ml the OMP26 peptides stimulated little or no response from OMP26-primed lymphocytes with the exception of T3+T4 peptide and the whole OMP26 molecule itself where significant stimulation was observed (P<0.001) (data not shown). In contrast, compared to naive lymphocytes, a peptide concentration of 10 µg/ml stimulated significant increases in lymphocyte proliferation ( Figure 1 ) in response to the T4 peptide (P<0.02; amino acid residues 140-197), T2+T3 peptide (P<0.05; amino acid residues 45-145) and T3+T4 peptide (P<0.001; amino acid residues 95-197). Lymphocyte proliferation stimulated by the individual peptides, T1 (amino acid residues 1-55), T2 (amino acid residues 45-100) or T3
(amino acid residues 95-145) and the T1a+T2 peptide (amino acid residues 24-100), did not differ significantly between the immunized versus non-immunized group.
These data suggested that in terms of lymphocyte proliferation, peptides that represented the C-terminus of OMP26 were more stimulatory than peptides that represented the N-terminus of the protein. 
Immunogenicity of OMP26 peptides
Immunogenicity of each of the individual peptides was confirmed by immunization of the rats (IPP/IT) with the individual peptides and subsequent analysis of the anti-OMP26 sera using both enzyme linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR). All antipeptide sera were reactive with their individual immunizing peptides, in addition to being reactive to the whole OMP26 protein, with the exception of the anti-T1 sera (Table 1) . These sera were then used to determine whether the peptides were surface exposed on NTHi whole cells by flow cytometry.
Determination of surface-exposed regions of OMP26
Antibodies to the 50-mer peptides (T1, T2, T3, T4) all showed distinct and reproducible shifts of the curve to the right ( Figure 3 ) which indicated binding of antibody to native structure on the bacterium. In addition, antisera to the 100-mer peptide T1a+T2 also showed a distinct shift to the right. In comparison, antisera to the 9 100 mer T2+T3 peptide demonstrated a lesser but consistent shift to the right whilst antisera against the T3+T4 peptide gave results similar to the non-immune serum.
Antibody responses assessed by ELISA and SPR analysis
Reactivity of mouse anti-OMP26 antibodies to OMP26 peptides B-cell epitope regions of OMP26 were examined in mice using pooled anti-OMP26 sera. The antibody responses against the OMP26 protein and the OMP26 peptides in the mouse were measured using ELISA and SPR. In mice, the predominant reactivity measured by ELISA was seen against the T2+T3 peptide, regardless of immunization regime ( Figures 4A, 4B ). Minor reactivity was also observed against the T1a+T2 peptide in the IPP/IT immunized group ( Figure   4A ), whilst in the IP immunized group, low level reactivity was also observed in the T3 and T3+T4 peptides ( Figure 4B ).
Similarly, SPR analyses showed predominant OMP26 reactivity against the T2+T3 peptide regardless of immunization regime ( Figures 4C and 4D) . In both the IPP/IT and IP immunization groups, low levels of reactivity were also observed against the T2, T3, T4, T1a+T2 and T3+T4 peptides, whilst no reactivity was observed for the T1 peptide. These data indicated that immunization of mice with OMP26 protein yielded the production of antibodies with affinity primarily to the larger T2+T3 peptide, which represents the mid-region of OMP26 (AA 45-145).
Reactivity of rat anti-OMP26 antibodies to OMP26 peptides
The antibody responses against the OMP26 protein and the OMP26 peptides in the rat were measured using ELISA and SPR and the IPP/IT and IP immunization regimens ( Figure 5 ).
In the rats immunized IPP/IT, a predominant response was observed against the T2+T3 peptide using ELISA, and minor reactivities were observed against the T2, T3, T1a+T2 and the T3+T4 peptides ( Figure 5A ). For animals immunized IP, the ELISA results again showed a substantial response against the T2+T3 peptide ( Figure 5B ). In addition, similar response was observed against the T1a+T2 peptide with substantially less reactivity stimulated in response to T3 and T3+T4 peptides.
In general, reactivity of rat serum assessed using SPR was greater and thus resulted in greater overall reactivity to the OMP26 peptides than observed with the ELISA.
Serum from rats immunized IPP/IT demonstrated substantial reactivity against T2+T3 peptide and lesser absolute responses were observed against the T2 and T3 peptides in comparison to the non-immune sera ( Figure 5C ). In animals immunized IP, the SPR reactivity provided even greater responses by the rat serum antibodies with the predominant response observed to the T2+T3 peptide. Substantial responses were also observed against the T2, T3, T1a+T2 and T3+T4 peptides ( Figure 5D ).
Therefore, as observed with mice, the response induced in rats by immunization with OMP26 yielded antibodies with greater affinity to the mid-region of the protein.
Reactivity of chinchilla anti-OMP26 antibodies to OMP26 peptides
The antibody responses against the OMP26 protein and the OMP26 peptides in the chinchilla after subcutaneous (SC) immunization were also measured using SPR and the results are shown in Figure 6 . Chinchilla anti-OMP26 antibodies exhibited the greatest overall reactivity to the T2+T3 peptide. Peptides T2, T3, and T4
showed lesser reactivity, whilst the T3+T4 peptide exhibited the lowest level of reactivity among the panel of peptides. Little antibody reactivity was observed to peptides T1 and T1a+T2.
Relative reactivity score
In order to summarise the data across species and immunization regimes, a relative reactivity score was calculated against the OMP26 response. The OMP26 response was assigned a relative reactivity score of 5 and the responses of the other OMP26 peptides were ranked against the OMP26 reactivity such that a response to an individual peptide that was 10-20% of the reactivity to OMP26 protein was scored as 1, 20-40% as 2, 40-60% as 3, 60-80% as 4, 80-100% as 5. No significant reactivity was detected against the T1 or T4 peptides regardless of species or immunization regime, although the chinchilla did demonstrate some reactivity to T2. Some reactivity was observed in response to all other peptides, with the T2+T3 peptide demonstrating the greatest activity ( Figure 7 ). Therefore, in terms of identification of potential B-cell epitope(s) within OMP26, antibodies against the mid-region of the protein consistently yielded the greatest reactivity, regardless of rodent species or immunization regime.
DISCUSSION
NTHi is recognised as a significant human pathogen 24 and has become the focus of attention towards the development of an effective vaccine against NTHi infections. Previous investigations have identified the efficacy of OMP26 as a potential vaccine antigen [16] [17] [18] . The current study examined the immunological recognition of T-and B-cell epitopes within truncated OMP26 to further characterize this vaccine candidate.
A series of overlapping peptides was constructed to localize the immunologically important regions for the OMP26. These peptides utilized the amino acid sequence of OMP26 identified in the strain NTHi-289 and included the 23-amino acid leader peptide. Previous studies have shown that the inclusion of the leader peptide and signal sequence in the recombinant OMP26 increased efficacy in a rodent model of acute respiratory infection 17 .
In the current study, each OMP26 peptide overlapped the preceding and/or subsequent peptide by 6-11 amino acid residues. The OMP26 peptide constructs consisted of four overlapping peptides (T1-T4) of approximately 50 amino acids in length that spanned the entire OMP26 sequence. In addition, combination peptides of approximately 100 amino acids in length (T1a+T2 to T3+T4) were designed to include the adjacent regions of each of the T1-T4 peptides. This design increased the opportunity for detection of all immunologically relevant regions within OMP26 in our analysis and thus provides the first detailed molecular insight into the basis of immune reactivity to OMP26.
In the rat, lymphocyte proliferative responses following priming with OMP26
protein showed strong antigen specific responses to both T4 and the T3+T4 peptides with the magnitude of the T3+T4 peptide exceeding that of the T4 alone. However, 13 individually, T2 and T3 failed to elicit a significant proliferative response. It is concluded that T-cell recognition is enhanced in the shared amino acid region between T3 and T4 and T-cell epitopes for OMP26 are located between amino acid residues 95 to 197, specifically the overlapping amino acid region between T3 and T4, upstream of amino acid residue 140. In addition, an OMP26-primed proliferative response was observed to the combined peptide T2+T3 but not to the individual T2 or T3 peptides suggesting that T-cell epitopes for OMP26 may also occur in the shared amino acid region between T2 and T3 (amino acid residues 94 to 100). When rats were immunized with each of the OMP26 peptides individually, the only lymphocyte proliferative response observed to the OMP26 protein was for the T3+T4 peptide.
This supports the identification of a T-cell epitope within the T3+T4 peptide which is most likely located in the overlapping region and may be conformational although typically linear amino acid motifs are more readily recognized by the major histocompatibility complex (MHC) molecules 25 .
Processing of the OMP26 protein in this study resulted in a peptide with similar flanking amino acid residues or similar conformation to that of the T3+T4 peptide, and presumably similar affinity for the MHC molecules. Lymphocytes primed with T4 and T2+T3 peptides did not prime any T-cell response, in contrast to the T3+T4 peptide-primed lymphocytes, despite proliferative responses to these peptides occurring in lymphocytes primed with the whole OMP26. Changes in the flanking amino acids and/or conformation of the T4 and the T2+T3 peptides may account for this failure and are of importance for subsequent vaccine designs utilizing epitopes.
Selection of T-cell epitopes may include competitive binding between the processed peptides contained within a single antigenic molecule for MHC molecules 14 26 . Thus, only the peptides with the highest affinity to MHC molecules are ultimately presented to T-cells and the competition would be void when inoculation uses only a single peptide 25 . The lack of apparent difference between the extent of proliferation generated by the T3+T4 peptide and intact OMP26 protein suggests that the T3+T4 region has highest affinity binding for MHC molecules in the current model. although, the T2+T3 region may also be resistant to the extracellular medium encountered by these two immunization routes resulting in the identical B-cell recognition patterns. The route of immunization can also alter both the hierarchical organization of B-and T-cell epitopes [27] [28] [29] , as well as, the titre and affinity of antibody responses 30 . Use of multiple animal species (chinchilla, mice and rats) and immunization routes in the present study showed that the immunodominant B-cell epitopes of OMP26 are located towards the centre of the molecule between amino acid residues 45-145 (T2+T3).
In this study, the T2+T3 peptide exhibited the highest reactivity in mouse and rat anti-OMP26 sera regardless of immunization regime. For the development of a peptide based vaccine, the T2+T3 peptide would be a lead candidate for a genetically diverse human population.
Following SC immunization of chinchillas, anti-OMP26 sera also strongly recognized peptides T2, T3 and T4. Whilst antibody recognition levels to these peptide were not as high as those to the T2+T3 peptide. It does suggest additional Bcell epitopes within the T2, T3 and T4 regions.
Immune sera generated from rats immunized IP with OMP26 also demonstrated strong reactivity to the T1a+T2 peptide. Thus, apart from the T2+T3 region, additional B-cell epitopes may be located between amino acid residues 24 and 100.
The T1 peptide (amino acid residues 1-50) was not recognized by any immune sera from all three animal species tested and the T4 peptide (amino acid residues 140-197) was not recognized by the immune serum pools from both mice and rats. This lack of antibody reactivity suggests that the T1 and T4 regions were sequestered or inaccessible despite clear expression on the surface of NTHi cells being detected by flow cytometry. This finding is suggestive of less surface exposure of these regions and is consistent with evidence from previous studies showing a hydrophobic character exists at the N-terminal and C-terminal regions of OMP26 17 . The lack of response to T1 and T4 peptides suggest that these peptide regions are not immunogenic, however, conformational diversion by T2+T3 dominance 31 or assay bias cannot be excluded. Assay bias in this study is unlikely as antibody recognition patterns obtained from both ELISA and SPR were mostly similar despite potential differences in the orientation of the bound peptides on the microtiter plates and biosensor chips.
Anti-OMP26 serum pools from all three animal species strongly recognized the T2+T3 region, but reactivities to the T2 or T3 region were also detected by SPR.
Reactivity to the individual T2 and T3 regions are interesting and do not approach the level stimulated by the T2+T3 region. Whilst additional epitopes cannot be excluded, it is likely that the anti-OMP26 sera were reactive to the shared amino acid region between the T2 and T3 regions.
Since the majority of B-cell epitopes are discontinuous in nature 32, 33 , it is also possible that these identified B-cell epitopes are conformational. The sequence within T2+T3 region may have brought amino acids into spatial proximity to form the conformation that resembles the OMP26 protein, and thus allowing antibodies raised against the whole protein to bind most efficiently.
Previous experiments involving immunolabeling of NTHi with antisera to OMP26 showed surface binding of gold-conjugated particles by transmission electron microscopy 16 , suggesting at least one surfaced exposed region on OMP26. 
MATERIALS AND METHODS
Bacterial strains, plasmids and growth conditions
This study used NTHi-289, a biotype I strain isolated from the sputum of a patient with chronic bronchitis 16 . Bacteria were grown at 37 o C in 5% CO 2 on brain heart infusion agar (Oxoid, UK) supplemented with 5% (v/v) defibrinated horse blood (BioMerleux, Australia). The concentration of purified OMP26 peptides was determined by a micro bicinchoninic acid (BCA) kit (Thermo Scientific, USA) as per the manufacturer's instructions. Amino acid sequences for the OMP26 peptides are shown in Table 3 . IPP/IT Immunization. Mucosal immunizations were performed for the mice and rats using an IPP/IT approach, as previously described 9, 35, 36 . Twenty one days after the first immunization, animals were euthanized using pentobarbital sodium overdose and tissue harvest and blood collection were performed. Blood volumes of 22 0.5-1 ml (mice) or 8-10 ml (rats) were collected by cardiac puncture into plain 1ml or 10 ml blood collection tubes (Sarstedt, Germany). Sera were pooled by cohort, peptides. Data were analyzed for statistical significance by a fully factorial analysis of variance (Macintosh Systat; Systat Software, USA) using log 10 -transformed data.
Escherchia coli
Antigen-specific ELISA
Immunogenicity of OMP26 peptides to induce antibody responses was examined by testing rat antipeptide sera, generated by immunization using individual OMP26
peptides, against the immunizing peptide and the whole OMP26 protein 16 . Antigenspecific ELISA were performed and standardized as previously described by Kyd,
Cripps, Novotny, Bakaletz 18 . There was minimal background reactivity against an E.coli antigen control for both immune and non-immune animals.
Surface plasmon resonance analysis
Serum and OMP26 protein and peptide interactions were assessed by SPR using the Biacore 3000 instrument (GE Healthcare Life Sciences, USA) as previously 
Flow cytometry
Flow cytometry was used to determine whether antibodies induced by immunization with OMP26 or peptides could bind to the surface of NTHi. To remove any potential E. coli antibodies that may have cross-reacted with NTHi, sera were pre-absorbed with E. coli prior to flow cytometry as previously described 40 .
NTHi-289 was grown as previously described 16 
